All conditions

Retinal Vein Occlusion and Diabetic Macular Oedema

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

880
Trials on record
47
Recruiting now
1
Australian sites
9
Phase 3 trials
4
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Retinal Vein Occlusion and Diabetic Macular Oedema →

Get alerts when Retinal Vein Occlusion and Diabetic Macular Oedema trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Retinal Vein Occlusion and Diabetic Macular Oedema

Retinal vein occlusion (RVO) and diabetic macular oedema (DME) are both conditions that affect the back of the eye, specifically a small but very important area called the macula, which is responsible for the sharp, detailed central vision you use for reading, recognising faces, and driving. In RVO, a tiny vein in the retina becomes blocked, causing fluid and blood to leak into the surrounding tissue. In DME, which is a complication of diabetes, high blood sugar levels over time damage the small blood vessels in the retina, also leading to fluid build-up in the macula. In both cases, this swelling can cause vision to become blurry or distorted, and if left untreated, may lead to permanent vision loss.

These conditions are more common than many people realise. In Australia, DME affects a significant number of the approximately 1.3 million Australians living with diabetes, and RVO is one of the most common retinal vascular conditions seen by eye specialists, becoming more likely with age, high blood pressure, and other cardiovascular risk factors. Both conditions can affect people of working age as well as older Australians, and can have a real impact on daily life and independence.

When it comes to managing these conditions, Australian eye specialists (ophthalmologists) have several approaches available. The most widely used current treatments involve injections of medication directly into the eye, known as intravitreal injections, which work to reduce swelling and, in some cases, improve vision. Laser treatment and corticosteroid implants are also used in certain situations. Treatment often requires ongoing appointments over many months, and your eye specialist will work with you to find the approach that suits your individual circumstances. If you have questions or concerns, your ophthalmologist or GP is the right person to speak with.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Retinal Vein Occlusion and Diabetic Macular Oedema in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Retinal Vein Occlusion and Diabetic Macular Oedema

4 medicines listed on the PBS for Retinal Vein Occlusion and Diabetic Macular Oedema. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 4 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Aflibercept Eylea, Afqlir Branch retinal vein occlusion with macular oedema AU$269.54 Authority required
Dexamethasone Ozurdex Branch retinal vein occlusion with macular oedema AU$1091.84 Authority required
faricimab Vabysmo Branch retinal vein occlusion with macular oedema AU$827.4 Authority required
Ranibizumab Lucentis Branch retinal vein occlusion with macular oedema AU$689.04 Authority required
Aflibercept Eylea, Afqlir Central retinal vein occlusion with macular oedema AU$269.54 Authority required
Dexamethasone Ozurdex Central retinal vein occlusion with macular oedema AU$1091.84 Authority required
faricimab Vabysmo Central retinal vein occlusion with macular oedema AU$827.4 Authority required
Ranibizumab Lucentis Central retinal vein occlusion with macular oedema AU$689.04 Authority required
Aflibercept Eylea, Afqlir Diabetic macular oedema (DMO) AU$269.54 Authority required
Dexamethasone Ozurdex Diabetic macular oedema (DMO) AU$1091.84 Authority required
faricimab Vabysmo Diabetic macular oedema (DMO) AU$827.4 Authority required
Ranibizumab Lucentis Proliferative diabetic retinopathy (PDR) and/or Diabetic macular oedema (DMO) AU$689.04 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Retinal Vein Occlusion and Diabetic Macular Oedema currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Retinal Vein Occlusion and Diabetic Macular Oedema.

View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Retinal Vein Occlusion and Diabetic Macular Oedema by country. Australia is highlighted.

Showing the top 10 of 39 countries with trial sites.

Clinical trials for Retinal Vein Occlusion and Diabetic Macular Oedema

Showing 52 of 52 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00168324 · Allergan Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 1 March 2008
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇱 IL🇲🇽 MX +5 more

**Who might be able to join this trial:** - You are 18 years of age or older and have swelling in the central part of your retina (called macular edema) caused by a blocked vein in your eye - Your vision in at least one eye has gotten worse because of this swelling, with eyesight of 20/50 or poorer (meaning you need to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01599650 · Novartis Pharmaceuticals Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 May 2015
🇦🇺 AU🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇬🇷 GR🇭🇺 HU🇮🇪 IE +9 more

Who might be able to join this trial: - You must be willing and able to sign a consent form before any study tests are done. - Your vision problems must be caused only by fluid build-up in the centre of your eye (macular oedema) due to a blockage in a branch vein in your eye (branch retinal vein occlusion). - Your visi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04740905 · Hoffmann-La Roche Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 6 July 2022
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇷 BR🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE +14 more

**Who might be able to join this trial:** - You have swelling in the central part of your retina (the back of your eye) caused by a blocked vein in the eye, and this was diagnosed no more than 4 months ago - Your vision in the affected eye falls within a specific range — roughly between 20/40 and 20/400 on a standard...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04740931 · Hoffmann-La Roche Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 9 August 2022
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇷 BR🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE +14 more

**Who might be able to join this trial:** - You have swelling at the centre of your retina (the back of your eye) caused by a blocked vein in the eye, and this was diagnosed no more than 4 months before the screening visit - Your vision (with glasses or contact lenses if you wear them) falls within a specific range —...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06701721 · Therini Bio Pty Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2027
🇦🇺 AU

Who might be able to join this trial: - People who are willing and able to understand the study procedures and risks, and can provide written consent before any study-related activities begin - People aged 18 to 80 years old (inclusive) at the time of giving consent - People who have been diagnosed with Diabetic Macula...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07519707 · University of California, San Francisco Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with diabetes, with or without an eye condition related to diabetes (called diabetic retinopathy) - Your upcoming clinic visit at ZSFG is specifically for managing your diabetes or diabetes-related eye condition - You can speak and understand English or Sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01496625 · National Eye Institute (NEI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - People who are able to understand and sign a consent form, or who are minor children with a parent or legal guardian who can sign on their behalf. - People who have been diagnosed with a retinal eye disease, have eye symptoms that have not yet been diagnosed, or are healthy indiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02669953 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇦🇹 AT

Who might be able to join this trial: - Adults aged 50 years or older - People who have been receiving ranibizumab injections to treat wet age-related macular degeneration (a condition causing vision loss) for up to one year - People whose vision in the eye being studied measures at least 20/400 on a standard eye chart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03161652 · Carmen Clapp Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇲🇽 MX

Who might be able to join this trial: - You are between 40 and 69 years old (inclusive). - You are male or female and have been diagnosed with mild or moderate diabetic macular edema (a diabetes-related eye condition causing swelling), non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy and ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03680794 · CHU de Reims Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years old - People who are affiliated with the French social security system - People who are willing to take part in the study **Who may not be able to join:** - People who have received certain eye or immune-related treatments (specifically anti-VEGF...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04008121 · MediBeacon Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older (men and women are both welcome) - Women who cannot become pregnant, or women who are willing to use adequate birth control during the trial - Men who are willing to either avoid sexual intercourse or use adequate birth control from the da...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04187443 · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 October 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with type 1 or type 2 diabetes, confirmed using standard medical guidelines. - You are able to follow the study instructions and are expected to attend all required visits and complete all study steps. - You agree to use reliable birth control during the s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04505618 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who are able to give their own consent to participate - People who are able to cooperate with tests and follow study instructions - People whose eye scans show clear images with good signal quality (confirm with trial site) **Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04910503 · Centre Hospitalier Universitaire Dijon Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2030
🇫🇷 FR

**Who might be able to join this trial:** - People who have given their free, written, and informed consent to participate - Adults (18 years of age or older) - People with diabetic macular oedema (swelling in the central part of the retina) that has been treated but is still present after at least 2 years of treatmen...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05728476 · Tianjin Medical University Eye Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People (and their families) who fully understand the study and are willing to sign a consent form - People who have been diagnosed with type 1 or type 2 diabetes - People whose HbA1c blood sugar level was below 10% within the last 3 months - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05802329 · Ocugen Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with either Type 1 or Type 2 Diabetes. - People whose reduced vision is mainly caused by diabetic macular oedema (swelling in the central part of the retina caused by diabetes). - People whose eye scan results show a specific level of retinal s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05916391 · Frontera Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to follow the study procedures throughout the trial. - People who are 18 years of age or older at the time of signing the consent form. - People who have been clinically diagnosed with centre-involving diabetic macular oedema (a type of swelling in...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06305416 · Incepta Pharmaceuticals Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2025
Bangladesh

**Who might be able to join this trial:** - People aged 18 years or older - People who are able to give written consent and follow the study requirements for the full duration of the trial - People who have been diagnosed with type 1 or type 2 diabetes, supported by lab results, or current regular use of insulin or or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06492876 · Frontera Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 November 2024
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to follow the study procedures throughout the trial - People aged 18 to 74 years old at the time of signing the consent form - People who have been clinically diagnosed with centre-involving diabetic macular oedema (a specific type of swelling in t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06536491 · Eclipse Life Sciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People who are willing and able to sign a consent form (or have a legal representative do so) and are able to attend all study visits and take part in all examinations - People who have been diagnosed with dia...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06549023 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇸🇪 SE

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with either Type 1 or Type 2 Diabetes and have recently been diagnosed with a condition called Proliferative Diabetic Retinopathy (PDR), which is an advanced stage of diabetic eye disease - People whose vi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06595355 · Isfahan University of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 22 September 2025
Iran

**Who might be able to join this trial:** - People who have swelling in the central part of the retina (the macula), with the central thickness measuring more than 300 microns on a specific eye scan called an OCT - People who have not received a specific eye injection called bevacizumab in the last 3 months, and have n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06610747 · Zhongshan Ophthalmic Center, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with type 1 or type 2 diabetes - People who are currently using insulin or oral diabetes medications on a regular basis to manage their diabetes - People who live within a 2-hour drive of the hospital or clinic w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06708260 · EnnovaBio Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to provide written consent to take part in the study. - People who understand the full study process, agree to take their medications as directed, complete all required assessments on time, and follow all study rules including restrictions on other...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06845163 · Alexandria University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who have Type 2 diabetes, are being treated with premixed insulin and metformin, and have been diagnosed with diabetic macular edema (a swelling in the central part of the retina) that affects the centre of their vision. - People whose eye scan (a specific type of ret...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06893965 · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇫🇷 FR

Who might be able to join this trial: - People aged 18 or older - People for whom a specific eye medicine called Aflibercept 8mg (also known as EYLEA 8mg) has been recommended by their doctor - People who are either new to this type of eye treatment, or who have switched from another similar treatment because their pre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06914778 · Hywel Dda Health Board Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with type 2 diabetes - People aged between 18 and 80 years old (inclusive) Who may not be able to join: - People who are unable or unwilling to give their consent to take part in the study - People who have previously received injections into the e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06929507 · University Hospital, Alexandroupolis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 March 2026
🇬🇷 GR

**Who might be able to join this trial:** - You have been diagnosed with diabetes. - You have one of the following eye conditions: diabetic macular edema (fluid/swelling in the eye due to diabetes), wet age-related macular degeneration (an eye condition causing central vision loss), or macular edema caused by a blocked...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06942520 · Sierra Eye Associates Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have Type 1 or Type 2 diabetes and have a specific type of swelling in the centre of the retina (called diabetic macular edema) that has been treated before - People whose most recent HbA1c blood sugar level result was 12% or below - People whose vision in the stu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06962839 · Boehringer Ingelheim Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇯🇵 JP🇵🇱 PL🇸🇰 SK🇬🇧 GB +1 more

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with type 1 or type 2 diabetes, with a blood sugar control measurement (HbA1c) below 12%, and whose diabetes medication has been stable for at least 30 days before the study starts, with no major medication...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06984822 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with either Type 1 or Type 2 diabetes. - People who have diabetic swelling in the central part of the retina (the area responsible for sharp vision), where the swelling measures more than 280 microns thick and fluid-filled pockets are visible within...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06985706 · Belfast Health and Social Care Trust Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 November 2028
🇬🇧 GB

**Who might be able to join this trial:** - Adults over 18 years of age - People who have been diagnosed with either Type 1 or Type 2 diabetes - People who initially presented with severe fluid/swelling in the central part of the retina (a specific measurement of 400 micrometres or more on eye scans) - People who are...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07002372 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are getting your very first injection into the eye (called an intravitreal injection) for a retinal eye condition - You are mentally able to make your own decisions and can communicate clearly without difficulty - You are willing to read and sign a consent form agreeing t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07038967 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇬 EG

Who might be able to join this trial: - People who are 18 years of age or older - People of any sex - People who have been diagnosed with a mild to moderate clouding of the eye's lens (Grade I or Grade II nuclear cataract) AND a specific type of swelling in the back of the eye related to diabetes that does not affect t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07133438 · First Affiliated Hospital of Chongqing Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 May 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with retinal vein occlusion (a blockage in the blood vessels of the retina) that meets recognised international diagnostic standards - People aged between 18 and 80 years old (any gender) - People who have not previously received any treatment for t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07205887 · EyeBiotech Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

Who might be able to join this trial: **General:** - A person must be willing and able to understand the study procedures and risks, and sign a written consent form before any study activities begin **For people with a new diagnosis of wet age-related macular degeneration (wet AMD) who have not yet received treatment...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07245082 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 August 2028
🇹🇼 TW

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with type 2 diabetes (based on your medical records, a diagnosis code, or because you take medication to lower blood sugar) - You are willing to take part in the study and have signed the consent form - You are able to compl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07259928 · Annexin Pharmaceuticals AB Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to give written informed consent and follow all study requirements - Adults aged 18 or older at the time of giving consent - Women who are confirmed to have no childbearing potential, as defined by the Clinical Trial Facilitation Group guideli...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07295704 · The General Authority for Teaching Hospitals and Institutes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2026
🇪🇬 EG

**Who might be able to join this trial:** - People aged 18 years or older, of any sex - People who have been diagnosed with either type 1 or type 2 diabetes - People whose vision in the affected eye is at least 20/400 (with the best possible glasses or contact lens correction) - People who have diabetic macular edema...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07308639 · Bayer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with at least one of the following eye conditions between January 1, 2009 and December 31, 2024: wet age-related macular degeneration (nAMD), diabetic macular edema (DME), or a blockage of a blood vessel in the retina (RVO) - If you have wet age-related ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07362927 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and attend follow-up appointments - People aged 18 or older - People who have been diagnosed with Type 1 or Type 2 diabetes and have a specific type of eye condition called diabetic macular edema (DME), where fluid causes swelling at...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07425522 · Genentech, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 17 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with type 1 or type 2 diabetes, as defined by major international health organisations - People whose HbA1c blood sugar level result is 12% or below (this is a measure of average blood sugar over several months) - People whose study eye has swe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449923 · EyePoint Pharmaceuticals, Inc. Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇧🇷 BR🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with swelling in the central part of the eye (called macular edema) linked to diabetic eye disease, whether they have received previous treatment for this condition or not. - People whose vision in the eye being studied falls within a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449936 · EyePoint Pharmaceuticals, Inc. Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇩🇪 DE🇮🇱 IL🇵🇱 PL🇸🇰 SK🇺🇸 US

"Who might be able to join this trial: - People who have been diagnosed with fluid build-up in the central part of the eye (called macular edema) linked to diabetes-related eye disease, whether or not they have had previous treatment for this condition. - People whose vision in the eye being studied falls within a spec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07458061 · Dr. Bryan Strelow Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older. - People who have been diagnosed with type 1 or type 2 diabetes, shown by currently taking insulin, currently taking diabetes tablets, or having a diagnosis confirmed by a doctor. - People who have a specific type of diabetes-related eye condit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07489131 · Alvotech Swiss AG Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇭🇺 HU

Who might be able to join this trial: - People who are 18 years of age or older at the time of signing the consent form - People who are willing and able to follow all study procedures and are likely to complete the study, based on the doctor's assessment - People who have been diagnosed with diabetic macular oedema (a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07515079 · Bio-Thera Solutions Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have agreed to take part voluntarily and are able to attend scheduled clinic visits and follow the study procedures - People who have been diagnosed with type 1 or type 2 diabetes and are between 18 and 80 years old (inclusive) - People whose study eye has a diabe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07520045 · Osijek University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇭🇷 HR

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with diabetic retinopathy, with or without swelling in the central part of the retina (called macular edema) - People whose condition means that eye injection treatment (called anti-VEGF therapy) is recommended un...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07550777 · Ataturk University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 June 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged 55 years or older - People who are able to give written agreement to take part in the study - **Patient group:** People who have been diagnosed with fluid swelling in the central part of the eye (macular edema) caused by diabetic eye disease, a blocked retinal ve...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07553429 · Boehringer Ingelheim Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 23 March 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have diabetic macular edema (a swelling in the central part of the retina caused by diabetes) that has been confirmed by a specific type of eye scan, with swelling measuring at a certain level or above. - People whose eyes are clear enough, and whose pupils can be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07592273 · AbbVie Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have moderately severe or severe non-proliferative diabetic retinopathy (a specific stage of eye disease caused by diabetes) where certain eye treatments can safely be delayed for at least 6 months from the first screening visit - People whose vision in the study...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07708142 · SANGMYUNG innovation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇰🇷 KR

Who might be able to join this trial: - People who are 19 years of age or older - People whose eye being studied has been diagnosed with swelling at the centre of vision (macular edema) caused by a blockage in a branch vein of the retina (BRVO) within the past 12 months, or a blockage in the central vein of the retina...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Retinal Vein Occlusion and Diabetic Macular Oedema. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Macular Disease Foundation Australia is the national body for macular conditions, including diabetic macular oedema and retinal vein occlusion.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.